Clinical Trials Browser

Fibrosarcoma, Leiomyosarcoma, Liposarcoma, Lymphangiosarcoma, Myosarcoma, Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Histiocytic Sarcoma

NCT04543890 2020-09-10

CTV

Phase 2 Unknown

300 enrolled

Thoracic

Small Cell Lung Cancer Limited Stage

NCT03816475 2019-06-17

LIPOMYX

Phase 2 Unknown

35 enrolled

Sarcoma

Sarcoma, Liposarcoma, Myxoid

NCT03419130 2018-12-07

Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer

Phase 2 Withdrawn

Genitourinary

Infiltrating Bladder Urothelial Carcinoma

NCT02947113 2017-11-30

HYPOLAN

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02460744 2015-06-02

2-weeks of Adjuvant Radiotherapy in Patients With Breast Cancer

Phase 2 Completed

50 enrolled

Breast

Breast Neoplasms

Clinical Trials

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate

SOAR

Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

SWIFT RT

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer

NOVEMBER

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

HypoRTCx-UG

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

Hypofractionated Radiation Therapy in Treating Participants With Breast Cancer Before Surgery

Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer

A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

Hypofractionated Radiotherapy for Soft Tissue Sarcomas

The Total Neoadjuvant Therapy for Soft Tissue Sarcoma of the Extremities

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy

Hypofractionated Radiotherapy for Prostate Cancer

Hypofraction

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC

Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

UN-RESARC

CTV

LIPOMYX

Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer

HYPOLAN

2-weeks of Adjuvant Radiotherapy in Patients With Breast Cancer